title: Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
abstract: BACKGROUND
  Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown.
  
  
  RESULTS
  In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01; P=0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02; P=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07).
  
  
  CONCLUSIONS
  In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone.
authors.affiliation: McMaster University, Population Health Research Institute, 237 Barton St E, Hamilton, ON L8L2X2 Canada. verdec@tin.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Verdecchia
authors.forename: Peter
authors.initials: P
authors.lastname: Sleight
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mancia
authors.forename: Robert
authors.initials: R
authors.lastname: Fagard
authors.forename: Bruno
authors.initials: B
authors.lastname: Trimarco
authors.forename: Roland E
authors.initials: RE
authors.lastname: Schmieder
authors.forename: Jae-Hyung
authors.initials: JH
authors.lastname: Kim
authors.forename: Garry
authors.initials: G
authors.lastname: Jennings
authors.forename: Petr
authors.initials: P
authors.lastname: Jansky
authors.forename: Jyh-Hong
authors.initials: JH
authors.lastname: Chen
authors.forename: Lisheng
authors.initials: L
authors.lastname: Liu
authors.forename: Peggy
authors.initials: P
authors.lastname: Gao
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Probstfield
authors.forename: Koon
authors.initials: K
authors.lastname: Teo
authors.forename: Salim
authors.initials: S
authors.lastname: Yusuf
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control*; D003971:Diastole; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D004562:Electrocardiography; D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D016017:Odds Ratio; D010919:Placebos; D015995:Prevalence; D016016:Proportional Hazards Models; D017257:Ramipril / Q000627:therapeutic use*; D012044:Regression Analysis; D013599:Systole; D000077333:Telmisartan
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D010919:Placebos; D017257:Ramipril; D000077333:Telmisartan